University of British Columbia
HAART interruption is a viable option when nadir CD4 cell counts are >250 cells/mm3
Published in Physician Law Weekly, January 4th, 2006
"The goal of the present study was to characterize outcome and predictors of outcome of treatment interruption (TI) in highly active antiretroviral therapy (HAART)-treated patients."
"A systematic chart/database review was conducted to identify patients with nadir CD4 cell counts >200 cells/mm3 and without acquired immunodeficiency syndrome -defining illnesses who underwent a TI," scientists in Canada report.
According to A.R. Toulson and colleagues at the University of British Columbia, "Collected data included...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
Source: Physician Law Weekly (2006-01-04)
More Articles from Physician Law Weekly
- Ciphergen Biosystems, Inc.
Breast cancer diagnostic development program launched - Eisai Co., Ltd.
Legal action begins over Aricept ANDA filing - Institute National d'Etudes Demographiques, Paris
AIDS triples the mortality of adults aged 25-44 years in Pointe-Noire - Kosan Biosciences Incorporated
Margaret Horn appointed senior VP, general counsel of cancer-focused bioscience company - MedImmune, Inc.
Pharma company announces senior management hires and promotions - Plastic Surgery
Surgeon speaks out in support of face transplant - More from this issue of Physician Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
